CYTK
NEUTRAL
$65.48
Live
Cytokinetics, Incorporated · NASDAQ
Target $92.82
(+41.8%)
$29.31
52W Range
$70.98
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 08, 2026
Market cap
$8.06B
P/E
N/A
ROE
N/A
Profit margin
N/A
Debt/Equity
N/A
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
90%
CYTK shows neutral fundamentals based on deterministic rules. Financial strength is stable (F-Score 5/9). Mixed signals with both opportunities and risks present.
Key Strengths
Company has established market presence
Key Risks
Limited historical data available for full assessment
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
40
Moderate
50
50
50
50
0
AI Verdict
CYTK shows neutral fundamentals based on deterministic rules. Financial strength is stable (F-Score 5/9). Mixed signals with both opportunities and risks present.
Key drivers: Company has established market presence, Limited historical data available for full assessment
Confidence
50%
Value
50/100
Rule-based valuation (P/E + Graham).
Positives
- Insufficient data for clear positives.
Watchpoints
No urgent risks highlighted.
Future
50/100
Rule-based growth outlook.
Positives
- Insufficient data for clear positives.
Watchpoints
No urgent risks highlighted.
Past
50/100
Historical performance + price trend: Shares moved +170.7% over 5Y and +81.9% over 1Y.
Positives
- Insufficient data for clear positives.
Watchpoints
No urgent risks highlighted.
Health
50/100
Balance sheet & liquidity (Z-Score: N/A).
Positives
- Insufficient data for clear positives.
Watchpoints
No urgent risks highlighted.
Dividend
0/100
Dividend policy fallback.
Positives
- Insufficient data for clear positives.
Watchpoints
- No regular dividend payments.
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$65.48
Analyst Target
$92.82
Upside/Downside
+41.8%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for CYTK and closest competitors.
Updated 2026-04-07
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
CYTK
Cytokinetics, Incorporated
Primary
|
+170.7% | +87.1% | +81.9% | +8.8% | +4.9% | -0.7% |
|
AVTR
Avantor, Inc.
Peer
|
-61.5% | -48.8% | -46.0% | -17.0% | +4.6% | -3.0% |
|
BIO
Bio-Rad Laboratories, Inc.
Peer
|
-49.6% | -35.1% | -15.9% | +12.3% | -1.7% | -5.4% |
|
ATR
AptarGroup, Inc.
Peer
|
-3.9% | +15.9% | -20.1% | -21.4% | +2.6% | +1.0% |
|
ARWR
Arrowhead Pharmaceuticals, Inc.
Peer
|
-23.4% | +107.3% | +265.3% | +85.2% | -10.6% | -8.0% |
CYT
Cytokinetics, Incorporated
Primary
5Y
+170.7%
3Y
+87.1%
1Y
+81.9%
6M
+8.8%
1M
+4.9%
1W
-0.7%
AVT
Avantor, Inc.
Peer
5Y
-61.5%
3Y
-48.8%
1Y
-46.0%
6M
-17.0%
1M
+4.6%
1W
-3.0%
BIO
Bio-Rad Laboratories, Inc.
Peer
5Y
-49.6%
3Y
-35.1%
1Y
-15.9%
6M
+12.3%
1M
-1.7%
1W
-5.4%
ATR
AptarGroup, Inc.
Peer
5Y
-3.9%
3Y
+15.9%
1Y
-20.1%
6M
-21.4%
1M
+2.6%
1W
+1.0%
ARW
Arrowhead Pharmaceuticals, Inc.
Peer
5Y
-23.4%
3Y
+107.3%
1Y
+265.3%
6M
+85.2%
1M
-10.6%
1W
-8.0%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
-13.27
PEG Ratio
N/A
P/B Ratio
-12.21
P/S Ratio
91.6
EV/Revenue
97.93
EV/EBITDA
-14.32
Market Cap
$8.06B
Profitability
Profit margins and return metrics
Profit Margin
N/A
Operating Margin
-1004.6%
Gross Margin
N/A
ROE
N/A
ROA
-27.08%
Growth
Revenue and earnings growth rates
Revenue Growth
+4.9%
Earnings Growth
N/A
Q/Q Revenue Growth
+4.89%
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
N/A
Current Ratio
4.53
Strong
Quick Ratio
4.45
Excellent
Cash/Share
$7.16
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$0.0B
Gross Margin
-488.0%
Op. Margin
-1004.6%
Net Margin
-1030.9%
Total Assets
$1.4B
Liabilities
$2.1B
Equity
$-0.7B
Debt/Equity
-3.16x
Operating CF
$-0.1B
CapEx
$-0.0B
Free Cash Flow
$-0.1B
FCF Yield
104%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-06
$N/A
2026-02-24
$-1.5
-9.7% surprise
2025-11-05
$-1.54
+1.6% surprise
2025-08-07
$-1.12
+17.9% surprise
Healthcare Sector Comparison
Comparing CYTK against 174 companies in the Healthcare sector
(15 bullish, 57 neutral, 102 bearish)
Revenue Growth
4.9%
This Stock
vs
114.69%
Sector Avg
-95.7%
(Slower)
Current Ratio
4.53
This Stock
vs
3.43
Sector Avg
+32.0%
(Stronger)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
CYTK
Cytokinetics, Incorporated
|
NEUTRAL | $8.06B | - | -% | -% | $65.48 | |
|
AVTR
Avantor, Inc.
|
BEARISH | $8.05B | - | -1.5% | -1.2% | $11.8 | Compare |
|
BIO
Bio-Rad Laboratories, Inc.
|
NEUTRAL | $8.0B | - | -9.5% | -26.4% | $296.57 | Compare |
|
ATR
AptarGroup, Inc.
|
NEUTRAL | $8.3B | 19.97 | 15.6% | 11.5% | $126.0 | Compare |
|
ARWR
Arrowhead Pharmaceuticals, Inc.
|
BULLISH | $7.71B | 34.41 | 75.5% | 18.5% | $55.05 | Compare |
CYTK
Cytokinetics,...
NEUTRAL
Mkt Cap
$8.1B
P/E
-
ROE
-%
Price
$65.48
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-01 | BLUM ROBERT I | Chief Executive Officer | Sale | 7,500 | $499,725 |
| 2026-03-31 | CALLOS ANDREW | Officer | Sale | 3,639 | $236,535 |
| 2026-03-18 | CALLOS ANDREW | Officer | Sale | 1,930 | $119,795 |
| 2026-03-17 | MALIK FADY IBRAHAM | Officer | Sale | 12,033 | $747,851 |
| 2026-03-17 | LEE SUNG | Chief Financial Officer | Sale | 4,935 | $306,710 |
| 2026-03-17 | CALLOS ANDREW | Officer | Sale | 8,542 | $530,885 |
| 2026-03-17 | BLUM ROBERT I | Chief Executive Officer | Sale | 36,601 | $2,274,752 |
| 2026-03-16 | CALLOS ANDREW | Officer | Sale | 1,709 | $104,300 |
| 2026-03-13 | MALIK FADY IBRAHAM | Officer | Stock Award | 27,306 | - |
| 2026-03-13 | HESSEKIEL JEFFREY J | Officer | Stock Award | 20,646 | - |
| 2026-03-13 | LEE SUNG | Chief Financial Officer | Stock Award | 20,646 | - |
| 2026-03-13 | CALLOS ANDREW | Officer | Stock Award | 33,966 | - |
| 2026-03-13 | BLUM ROBERT I | Chief Executive Officer | Stock Award | 75,258 | - |
| 2026-03-09 | MALIK FADY IBRAHAM | Officer | Sale | 2,907 | $176,513 |
| 2026-03-09 | CALLOS ANDREW | Officer | Sale | 2,582 | $156,779 |
BLUM ROBERT I
Chief Executive Officer
2026-04-01
7,500 shares
·
$499,725
CALLOS ANDREW
Officer
2026-03-31
3,639 shares
·
$236,535
CALLOS ANDREW
Officer
2026-03-18
1,930 shares
·
$119,795
MALIK FADY IBRAHAM
Officer
2026-03-17
12,033 shares
·
$747,851
LEE SUNG
Chief Financial Officer
2026-03-17
4,935 shares
·
$306,710
CALLOS ANDREW
Officer
2026-03-17
8,542 shares
·
$530,885
BLUM ROBERT I
Chief Executive Officer
2026-03-17
36,601 shares
·
$2,274,752
CALLOS ANDREW
Officer
2026-03-16
1,709 shares
·
$104,300
MALIK FADY IBRAHAM
Officer
2026-03-13
27,306 shares
HESSEKIEL JEFFREY J
Officer
2026-03-13
20,646 shares
LEE SUNG
Chief Financial Officer
2026-03-13
20,646 shares
CALLOS ANDREW
Officer
2026-03-13
33,966 shares
BLUM ROBERT I
Chief Executive Officer
2026-03-13
75,258 shares
MALIK FADY IBRAHAM
Officer
2026-03-09
2,907 shares
·
$176,513
CALLOS ANDREW
Officer
2026-03-09
2,582 shares
·
$156,779
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
BUY
17 analysts
Barclays
2026-04-06
Overweight
Overweight
Mizuho
2026-03-18
Outperform
Outperform
JP Morgan
2026-03-17
Overweight
Overweight
UBS
2026-03-06
Neutral
Neutral
Leerink Partners
2026-02-26
Outperform
Outperform
Citizens
2026-02-25
Market Outperform
Market Outperform
Needham
2026-02-25
Buy
Buy
RBC Capital
2026-02-20
Outperform
Outperform
Truist Securities
2026-02-03
Buy
Buy
B. Riley Securities
2026-01-21
Buy
Buy
Past News Coverage
Recent headlines mentioning CYTK from our newsroom.
Newest → oldest
No matching news yet.